PL-6983 for Sexual Dysfunction
PL-6983 is the lead compound in a new series of melanocortin receptor-specific peptides developed by Palatin Technologies. PL-6983 has demonstrated efficacy in inducing erections in animal models and in inducing sexual behavior in an animal model of female sexual dysfunction (FSD). In animal models at doses effective for a sexual response, PL-6983 resulted in significantly smaller increases in blood pressure compared to bremelanotide.
We are focusing development efforts on bremelanotide for FSD, but are continuing evaluation of PL-6983.